- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01193413
Soluble Triggering Receptor Expressed on Myeloid Cells in Severe Acute Pancreatitis (STREM-1)
Soluble Triggering Receptor Expressed on Myeloid Cells in Severe Acute Pancreatitis: a Marker of Infected Necrosis and Indicator of Treatment
Study Overview
Status
Conditions
Detailed Description
The major cause of death, next to early organ failure, is secondary infection of pancreatic or peripancreatic necrotic tissue, leading to sepsis and multiple organ failure. The diagnosis and treatment of infected necrosis in SAP remain a major challenge for clinicians. The necrotic infection is defined when microorganisms are isolated from the samples of ultrasound or computed tomography (CT) guided fine needle aspiration (FNA). Unfortunately, a negative biopsy result can not completely rule out infection and the repeated aspirations may lead to bleeding or iatrogenic infection. Moreover, whatever the microbiologic diagnostic procedure chosen, further laboratory processing and delays of 24 to 48 hours are required for definitive quantitative microbial culture results. Meanwhile, clinicians often feel uncomfortable about the diagnosis and may administer unneeded antibiotics while awaiting laboratory results.
Secondary infection of necrotic tissue in SAP patients is virtually always an indication for intervention. The traditional approach is open necrosectomy to completely remove the infected necrotic tissue. This invasive approach is associated with high rates of complications (34 to 95%) and death (11 to 39%).As an alternative to open necrosectomy, less invasive techniques, including percutaneous drainage and endoscopic (transgastric) drainage, are increasingly being used.These steps may postpone or even obviate surgical necrosectomy with reducing complications and death.It remains uncertain which intervention is optimal in terms of clinical conditions of these patients and the severity of local infection.
Therefore, many biologic markers have been studied in an effort to improve the diagnostic rate and determine the the severity of necrosis infection but with disappointing results. The triggering receptor expressed on myeloid cells (TREM-1) is a member of the immunoglobulin superfamily whose expression on phagocytes is up-regulated by exposure to bacteria and fungi. TREM-1 mediates the acute inflammatory response to microbial products.[27] TREM-1 is also shed by the membrane of activated phagocytes and can be found in a soluble form in body fluids. We evaluated whether the lever of soluble TREM-1 (sTREM-1) in FNA fluid from patients who suspected infection is a good marker of secondary infection of necrotic tissue and an indicator of the proper treatment between drainage and necrosectomy.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Shanghai, China, 200433
- Changhai Hospital, Second Military Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- 18 years of age or older
- Diagnosis of severe pancreatitis
- Pancreatic or peripancreatic necrosis
- Body temperature at least 38.3°C
- Leukocytosis (more than 10,000 leukocytes per cubic millimeter) or leukopenia (fewer than 4000 leukocytes per cubic millimeter)
Exclusion Criteria:
- A flare-up of chronic pancreatitis
- End-stage chronic diseases (including pancreatic and bile duct cancer)
- Previous drainage or surgery for confirmed or suspected infected necrosis
- An acute intraabdominal event (e.g., perforation of a visceral organ, bleeding, or the abdominal compartment syndrome)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Non-infected necrosis group
There is no necrosis infection in severe acute pancreatitis.
|
Single drainage group
The patients with necrosis infection in severe acue pancreatitis were cured by single drainage.
|
Combined surgery group
If there was no clinical improvement after single drainage about 7 days, an open necrosectomy was performed in the patients with necrosis infection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The level of sTREM-1 in fine needle aspiration fluid
Time Frame: more than 14 days after entry
|
The fluid level of sTREM-1 was used to diagnose the secondary infection of necrotic tissues in severe acute pancreatitis and select the proper treatment between single drainage and necrosectomy.
|
more than 14 days after entry
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The fluid level of Interleukin-6
Time Frame: more than 14 days after entry
|
The fluid level of Interleukin-6 was used to diagnose the secondary infection of necrotic tissues in severe acute pancreatitis and select the proper treatment between single drainage and necrosectomy.
|
more than 14 days after entry
|
The fluid level of tumor necrosis factor-α
Time Frame: more than 14 days after entry
|
The fluid level of tumor necrosis factor-α was used to diagnose the secondary infection of necrotic tissues in severe acute pancreatitis and select the proper treatment between single drainage and necrosectomy.
|
more than 14 days after entry
|
The serum level of sTREM-1
Time Frame: more than 14 days after entry
|
The serum level of sTREM-1 was used to diagnose the secondary infection of necrotic tissues in severe acute pancreatitis and select the proper treatment between single drainage and necrosectomy.
|
more than 14 days after entry
|
The serum level of C-reactive protein
Time Frame: more than 14 days after entry
|
The serum level of C-reactive protein was used to diagnose the secondary infection of necrotic tissues in severe acute pancreatitis and select the proper treatment between single drainage and necrosectomy.
|
more than 14 days after entry
|
The level of leukocyte count and neutrophil percentage
Time Frame: more than 14 days after entry
|
The level of leukocyte count and neutrophil percentage was used to diagnose the secondary infection of necrotic tissues in severe acute pancreatitis and select the proper treatment between single drainage and necrosectomy.
|
more than 14 days after entry
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Zhaoshen Li, MD, Changhai Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Changhai-100829
- 30772138 (Other Grant/Funding Number: National Natural Science Foundation of China)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatitis
-
Changhai HospitalUnknownChronic Pancreatitis | Idiopathic Chronic PancreatitisChina
-
Centre Hospitalier Universitaire de NiceRecruiting
-
Copenhagen University Hospital, HvidovreRecruitingFibrosis | Inflammation | Pancreatitis | Chronic Pancreatitis | Acute Pancreatitis | Recurrent PancreatitisDenmark
-
Tianjin Nankai HospitalCompletedAcute PancreatitisChina
-
Massachusetts General HospitalTerminatedChronic Pancreatitis | Acute Recurrent PancreatitisUnited States
-
Changhai HospitalEnrolling by invitationChronic Pancreatitis | Acute Pancreatitis | Healthy PeopleChina
-
Postgraduate Institute of Medical Education and...Completed
-
Dartmouth-Hitchcock Medical CenterCompleted
-
The Cleveland ClinicChiRhoClin, Inc.; The National Pancreas FoundationCompletedChronic PancreatitisUnited States